ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for discussion 登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。

IMMP Immutep Ltd

2.69
0.09 (3.46%)
取引時間後
最終更新日: 07:00:03
15分遅延
名称 銘柄コード 市場 種別
Immutep Ltd IMMP NASDAQ Depository Receipt
  前日比 前日比 % 現在値 時刻
0.09 3.46% 2.69 07:00:03
始値 安値 高値 終値 前日終値
2.73 2.60 2.74 2.69 2.60
この銘柄の詳細情報 »

最新ニュース

日付 時間 ソース タイトル
2024/5/0221:00GLOBEPositive Initial Clinical Data Reported from Immutep’s Efti..
2024/4/2921:00GLOBEImmutep Quarterly Activities Report Q3 FY24
2024/4/2421:00GLOBEImmutep Announces Positive Preliminary Topline Results from..
2024/4/1821:00GLOBEImmutep Appoints Leading Research Institute to Conduct..
2024/4/1721:00GLOBEImmutep Receives Positive Feedback from the Spanish..
2024/3/0522:00GLOBEImmutep Announces First Clinical Data from 90mg Dosing of..
2024/1/3106:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2024/1/3022:00GLOBEImmutep Quarterly Activities Report Q2 FY24
2024/1/0422:00GLOBEFirst Patient Dosed in Trial Evaluating Efti and the..
2023/12/2122:00GLOBEImmutep Receives Constructive Regulatory Feedback on..
2023/12/2120:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2023/12/0722:00GLOBEImmutep Receives A$2.6 million R&D Tax Incentive from French..
2023/11/2222:00GLOBEImmutep Announces Site Expansion for INSIGHT-003 Phase I..
2023/11/0922:00GLOBEImmutep Completes Enrollment in TACTI-003 Phase IIb Trial of..
2023/11/0622:00GLOBEImmutep Announces Completion of the Safety Lead-In and..
2023/11/0401:00GLOBEImmutep Announces New Biomarker Data from TACTI-002 Phase II..
2023/11/0319:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2023/11/0221:00GLOBEImmutep to Participate in November Investor Events
2023/10/3121:00GLOBEImmutep Quarterly Activities Report Q1 FY24
2023/10/2521:00GLOBEImmutep receives ~A$1.13 million R&D Tax Incentive
2023/10/2519:07EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2023/10/2421:00GLOBEImmutep Reports Promising Clinical Data from INSIGHT-003..
2023/10/2419:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2023/10/2321:00GLOBEImmutep’s Efti in Combination with KEYTRUDA® Generates..
2023/10/1621:00GLOBEImmutep Announces Publication of Abstracts at ESMO Congress..
2023/10/0321:00GLOBEImmutep Announces Abstract Accepted for Presentation at the..
2023/9/2121:00GLOBECommercial Manufacturing of Eftilagimod Alpha at 2000L Scale..
2023/9/0522:00GLOBEImmutep to Participate in September Investor Conferences
2023/8/0121:00GLOBEImmutep Receives Positive Scientific Advice from European..
2023/7/3121:00GLOBEImmutep Quarterly Activities Report Q4 FY23
2023/7/2821:00GLOBEFirst Patient Dosed in Chemotherapy-Free Triple Combination..
2023/7/2819:31EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2023/6/2721:00GLOBEImmutep Completes A$80 Million Capital Raise
2023/6/2021:00GLOBEImmutep Granted United States Patent for IMP761, a..
2023/6/0721:00GLOBEImmutep to Participate at the Jefferies Healthcare..
2023/6/0521:00GLOBEImmutep Reports Final Positive Data in 2nd Line Head and..
2023/6/0221:00GLOBEImmutep Successfully Completes Institutional Placement and..
2023/5/2921:00GLOBEImmutep Selects Charles River Laboratories for IMP761’s GLP..
2023/5/2621:00GLOBEImmutep Announces Publication of Abstracts for ASCO 2023..
2023/5/2521:00GLOBEImmutep Doses First Patient in AIPAC-003 Phase II/III Trial..
2023/5/2421:00GLOBEImmutep Announces Promising New Clinical Data from Triple..
2023/5/1721:00GLOBEImmutep’s Efti in Combination with Pembrolizumab Achieves..
2023/5/1621:00GLOBEImmutep Receives Positive Feedback from FDA on Late-Stage..
2023/5/0921:00GLOBEImmutep to Participate in the JMP Securities Life Sciences..

最近閲覧した銘柄

Delayed Upgrade Clock